COVID-19: NIAID Clinical Research Support Services (CRSS)
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 272201700078C-P00022-9999-2
Grant search
Key facts
Disease
COVID-19Start & end year
20212022Known Financial Commitments (USD)
$4,167,596Funder
National Institutes of Health (NIH)Principal Investigator
BAMBRA STROKESResearch Location
United States of AmericaLead Research Institution
PPD DEVELOPMENT LPResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Vaccine design and administration
Special Interest Tags
N/A
Study Type
Not applicable
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The purpose of this contract is to provide a broad range of research support services to the current and evolving NIAID-supported clinical research portfolio. The contract enables the NIAID to establish and maintain the robust and flexible resources required to facilitate and advance infectious disease research and establish and maintain support for product development activities for high priority vaccine, other prevention and therapeutic approaches. Support will be provided in four broad clinical research areas: a) clinical research management; b) clinical site assistance; c) clinical trial management and d) clinical trial compliance. This project will provide support services for the COVID-19 ACTIV2 Outpatient Monoclonal Antibodies And Other Therapies clinical trial.